- Home
- ANIP vs LILAK Comparison
ANIP vs LILAK Comparison
Compare ANIP & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIP | LILAK |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ANIP | LILAK |
|---|---|---|
| Price | $79.59 | $6.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $105.83 | $8.20 |
| AVG Volume (30 Days) | 409.7K | ★ 820.8K |
| Earning Date | 11-07-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | $826,880,000.00 | ★ $4,433,000,000.00 |
| Revenue This Year | $44.06 | $1.62 |
| Revenue Next Year | $9.06 | N/A |
| P/E Ratio | $46.26 | ★ N/A |
| Revenue Growth | ★ 48.87 | N/A |
| 52 Week Low | $52.74 | $4.23 |
| 52 Week High | $99.50 | $9.13 |
Technical Indicators
Market Signals| Indicator | ANIP | LILAK |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 20.93 |
| Support Level | $76.69 | $7.52 |
| Resistance Level | $80.29 | $7.59 |
| Average True Range (ATR) | 2.41 | 0.32 |
| MACD | -0.10 | -0.10 |
| Stochastic Oscillator | 37.74 | 2.24 |
Price Performance
Historical ComparisonAbout ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.